Samsung invests 14.5 billion won in C2N Diagnostics for Alzheimer's testing

Samsung C&T announced on the 13th that it will invest $10 million (about 14.5 billion won) in C2N Diagnostics in the United States through a life sciences fund established with its subsidiaries Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment.

According to the company, C2N Diagnostics is a firm that has developed technology to accurately measure and analyze protein biomarkers present in trace amounts in the blood.

Based on this technology, the company developed a blood test for Alzheimer’s disease and has participated in clinical trials for Alzheimer’s treatments and various central nervous system diseases to prove its technological capabilities.

The Alzheimer’s blood test developed by C2N Diagnostics can precisely measure levels of several proteins related to Alzheimer’s disease, such as amyloid beta, at a lower cost and with greater safety compared to traditional amyloid PET-CT tests or cerebrospinal fluid tests. C2N Diagnostics plans to apply for U.S. Food and Drug Administration (FDA) approval for its Alzheimer’s blood test service within the year.

Kim Jae-woo, vice president in charge of the life sciences business at Samsung C&T, said, “This fund investment has secured a foothold for entering the relevant field.”

Joel Brownstein, CEO of C2N Diagnostics, noted, “We possess differentiated competitiveness in the field of protein analysis through continuous technological innovation,” and added, “With this investment, we plan to strengthen our technological capabilities and secure talented individuals to expand our services overseas.”